Connexin-independent ganciclovir-mediated killing conferred on bystander effect-resistant cell lines by a herpes simplex virus-thymidine kinase-expressing colon cell line

Molecular Therapy

Volumn 2, Issue 5, 2000, Pages 515-523

  Drake, Richard R ^a   Pitlyk, Karen ^a   McMasters, Robyn A ^b   Mercer, Kelly E ^a   Young, Hannah ^a   Moyer, Mary Pat ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Bystander effect; Connexin; Ganciclovir; Gap junction; HSV thymidine kinase; Nucleotide transport; Suicide gene therapy

Indexed keywords

HERPES; SIMPLEXVIRUS;

CONNEXIN 43; GANCICLOVIR; THYMIDINE KINASE;

ARTICLE; CELL COUNT; CELL CULTURE; CELL DEATH; COLON TUMOR; ENZYMOLOGY; GENETICS; HERPES SIMPLEX VIRUS; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; VIROLOGY;

CELL COUNT; CELL DEATH; COLONIC NEOPLASMS; CONNEXIN 43; GANCICLOVIR; HUMANS; PHOSPHORYLATION; SIMPLEXVIRUS; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

EID: 0034323468     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0192     Document Type: Article

References (44)

1. Vulver, K. W., Ram, Z., Walbridge, S., Ishii, H., Oldfield, E. H., and Blaese, R. M. (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552.
2. Freeman, S. M., et al. (1993). The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53: 5274-5283.
3. Freeman, S. M., Whartenby, K. A., Freeman, J. L., Abboud, C. N., and Marrogi, A. J. (1996). In situ use of suicide genes for cancer therapy. Semin. Oncol. 23: 31-45.
4. Denning, C., and Pitts, J. D. (1997). Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum. Gene Ther. 8: 1825-1835.
5. Moolten, F. L., and Wells, J. M. (1990). Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 82: 297-300.
6. Drake, R. R., Wilbert, T. N., Hinds, T. A., and Gilbert, K. (1999). Differential ganciclovir mediated cell killing by glutamine-125 mutants of herpes simplex virus type 1 thymidine kinase. J. Biol. Chem. 274: 37186-37192.
7. Wei, S., et al. (1998). S-and G2-phase cycle arrests and apoptosis induced by ganciclovir in murine melanoma cells transduced with herpes simplex virus thymidine kinase. Exp. Cell Res. 241: 66-75.
8. Rubsam, L. Z., Davidson, B. L., and Shewach, D. S. (1998). Superior cytotoxicity with ganciclovir compared with acyclovir and 1-β-D-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-ex pressing cells: A novel paradigm for cell killing. Cancer Res. 58: 3873-3882.
9. 2-M arrest in cytoskeletal reorganization induced by cytotoxic nucleoside analogues. Cancer Res. 58: 3855-3865.
10. McMasters, R., Jones, K. E., Saylors, R. L., Hendrix, E. M., Moyer, M. P, and Drake, R. R. (1998). Lack of bystander killing in HSV-TK transduced colon cell lines due to deficient connexin 43 gap junction formation. Hum. Gene Ther. 9: 2253-2261.
11. Bi, W. L., Parysek, L. M., Warnick, R., and Stambrook, P. J. (1993). In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gene Ther. 4: 725-731.
12. Elshami, A. A., et al. (1996). Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 3: 85-92.
13. Mesnil, M., Piccoli, C., Tiraby, G., Willecke, K., and Yamasaki, H. (1996). Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA 93: 1831-1835.
14. Yang, L., et al. (1998). Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells. Hum. Gene Ther. 9: 719-728.
15. Boucher, P. D., Ruch, R. J., and Shewach, D. S. (1998). Differential ganciclovir mediated cytotoxicity and bystander killing in human colon carcinoma cell lines expressing herpes simplex virus thymidine kinase. Hum. Gene Ther. 9: 801-814.
16. L expression in human colon tumor cell lines transduced with HSV-thymidine kinase. Cancer Gene Ther. 7: 563-573.
17. Beck, C., Cayeux, S., Lupton, S. D., Dorken, B., and Blankenstein, T. (1995). The thymidine kinase/ganciclovir-mediated "suicide" effect is variable in different tumor cells. Hum. Gene Ther. 6: 1525-1530.
18. Ishii-Morita, H., et al. (1997). Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther. 4: 244-251.
19. Trinh, Q. T., Austin, E. A., Murray, D. M., Knick, V. C., and Huber, B. E. (1995). Enzyme/prodrug gene therapy: Comparison of cytosine deaminase; 5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prod rug systems in a human colorectal carcinoma line. Cancer Res. 55: 4808-4812.
20. Imaizumi, K., et al. (1998). Bystander tumoricidal effect and gap junctional communication in lung cancer cell lines. Am. J. Respir. Cell Mol. Biol. 18: 205-212.
21. Princen, F., et al. (1999). A cell type-specific and gap junction independent mechanism for the herpes simplex virus-1 thymidine kinase gene/ganciclovir-mediated bystander effect. Clin. Cancer Res. 5: 3639-3644.
22. Bai, S., Du. L., Lui, W., Whittle, I. R., and He, L. (1999). Tentative novel mechanism of the bystander effect in glioma gene therapy with HSV-TK/GCV system. Biochem. Biophys. Res. Commun. 259: 455-459.
23. Moyer, M. P., Manzano, L. A., Merriman, R. L., Staufffer, J. S., and Tanzer, L. R. (1996). NCM460, a normal colon mucosal epithelial cell line. In Vitro Cell. Dev. Biol. Animal 32: 315-317.
24. Kim, Y. G., Bi, W., Feliciano, E. S., Drake, R. R., and Stambrook, P. J. (1999). Ganciclovir-mediated cell killing and bystander effect is enhanced in cells with two copies of the herpes simplex virus thymidine kinase gene. Cancer Gene Ther. 7: 240-246.
25. Chen, C., Chang, Y., Ryan, P., Linscott, M., McGarrity, G. J., and Chiang, Y. L. (1995). Effect of herpes simplex virus thymidine kinase expression of ganciclovir-mediated cytotoxicity and the "bystander effect." Hum. Gene Ther. 6: 1467-1476.
26. Knowles, A. F., and Nagy, A. K. (1999). Inhibition of an ecto-ATP-diphosphohydrolase by azide. Eur. J. Biochem. 262: 349-357.
27. Freeman, S. M., Ramesh, R., and Marrogi, A. J. (1997). Immune system in suicide-gene therapy. Lancet 349: 2-3.
28. Vile, R. G., Castleden, S., Marshall, J., Camplejohn, R., Upton, C., and Chong, H. (1997). Generation of an anti-tumour immune response in a non-immunogenic tumour: HSV-TK killing in vivo stimulates a mononuclear cell infiltrate and a Th-1-like profile of intratumoral cytokine expression. Int. J. Cancer 71: 267-274.
29. Hall, S. J., Sanford, M. A., Atkinson, G., and Chen, S.-H. (1998). Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res. 58: 3221-3225.
30. Mullen, C. A., Anderson, L., Woods, K., Nishino, M., and Petropoulos, D. (1998). Ganciclovir chemoablation of herpes thymidine kinase suicide gene-modified tumors produces tumor necrosis and induces systemic immune responses. Hum. Gene Ther. 9: 2019-2030.
31. Bi, W., et al. (1997). An HSV-Tk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice. Cancer Gene Ther. 4: 246-252.
32. Kianmanesh, A. R., et al. (1997). A "distant" bystander effect of suicide gene therapy: Regression of nontransduced tumors together with a distant transduced tumor. Hum. Gene Ther. 8: 1807-1814.
33. Boucher, P. D., Ostruszka, L. J., and Shewach, D. S. (2000). Synergistic enhancement of herpes simplex virus thymidine kinase/ganciclovir-mediated cytotoxicity by hydroxyurea. Cancer Res. 4: 246-252.
34. Plesner, L. (1995). Ecto-ATPases: Identities and functions. Int. Rev. Cytol. 158: 141-214.
35. Smith, T. M., Lewis Carl, S. A., and Kirley, T. L. (1999). Mutagenesis of two conserved tryptophan residues of the E-type ATPases: Inactivation and conversion of an ecto-apyrase to an ecto-NTPase. Biochemistry 38: 5849-5857.
36. Todorov, L. D., et al. (1997). Neuronal release of soluble nucleotidases and their role in neurotransmitter inactivation. Nature 387: 76-79.
37. Gayle, R. B., et al. (1998). Inhibiton of platelet function by recombinant soluble ecto-ADPase/CD39. J. Clin. Invest. 101: 1851-1859.
38. Schuetz, J. D., et al. (1999). MRP-4: A previously unidentified factor in resistance of nucleoside-based antiviral druqs. Nat. Med. 5: 1048-1051.
39. Wijnholds, J., et al. (2000). Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl. Acad. Sci. USA 97: 7476-7481.
40. Connelly, M. C., Robbins, B. L., and Fridland, A. (1993). Mechanism of uptake of the phosphonate analog (5)-1 -(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vero cells. Biochem. Pharmacol. 46: 1053-1057.
41. Palu, G., Stefanelli, S., Rasu, M., Parolin, C., Balzarini, J., and De Clerq, E. (1991). Cellular uptake of phosphonylmethoxyalkylpurine derivatives. Antiviral Res. 16: 115-119.
42. Fiore, C., et al. (1998). The mitochondrial ADP/ATP carrier: Structural, physiological and pathological aspects. Biochimie 80: 137-150.
43. Gualix, J., Pintor, J., and Miras-Portugal, M. T. (1999). Characterization of nucleotide transport into rat brain synaptic vesicles. J. Neurochem. 73: 1098-1104.
44. Puglielli, L., Mandon, E. C., and Hirschberg, C. B. (1999). Identification, purification and characterization of the rat liver Golgi membrane ATP transporter. J. Biol. Chem. 274: 12665-12669.